GLP-1, GIP & Glucagon: Understanding Peptide Receptor Research
Semaglutide, tirzepatide and retatrutide are investigated through different receptor pathways. Understanding those pathways provides useful context for interpreting the research surrounding each compound.
What Is A Peptide Receptor?
Receptors are proteins that allow cells to respond to biological signalling molecules. Many metabolic hormones act by interacting with receptors on cells and triggering signalling processes inside those cells.
In research, describing a compound as a receptor agonist means that it interacts with a receptor and activates signalling through that receptor. The biological consequences depend on the receptor, tissue, signalling pathway and experimental context.
Three Important Metabolic Signalling Pathways
Three receptors are particularly relevant to the compounds discussed throughout TrimFast's research resources.
GLP-1
Glucagon-like peptide-1 is an incretin hormone involved in metabolic signalling. GLP-1 receptor activity is associated with processes including glucose regulation, insulin secretion and gastrointestinal signalling.
GIP
Glucose-dependent insulinotropic polypeptide is another nutrient-responsive hormone. GIP receptor signalling is investigated in relation to glucose and energy metabolism and is an important component of tirzepatide's pharmacology.
Glucagon
Glucagon is involved in energy regulation and glucose homeostasis. Glucagon receptor activity is particularly relevant to research into multi-receptor compounds such as retatrutide.
How The Three Compounds Differ
One useful way to understand the research landscape is to look at the receptor targets rather than simply treating all metabolic peptides as the same type of compound.
Tirzepatide is described in published research as a dual GIP and GLP-1 receptor agonist, while retatrutide is described as an agonist of the GIP, GLP-1 and glucagon receptors. :contentReference[oaicite:2]{index=2}
From Receptor Activity To Research Outcomes
Receptor Interaction
Researchers first consider which biological receptor or receptors a compound interacts with.
Cellular Signalling
Receptor activation can trigger downstream signalling processes that researchers can investigate experimentally.
Measured Endpoints
Clinical studies then examine defined outcomes in particular populations using specific research methods and endpoints.
Why Multi-Receptor Research Is Interesting
Semaglutide provides an example of research centred on GLP-1 receptor activity. Tirzepatide adds GIP receptor activity alongside GLP-1 signalling. Retatrutide extends this concept further by targeting GIP, GLP-1 and glucagon receptors.
This progression is scientifically interesting because researchers can investigate whether combining different signalling pathways produces different biological effects. It also creates additional questions around tolerability, dose-response relationships, metabolism and long-term outcomes.
The retatrutide Phase 2 trial, for example, specifically described the compound as an agonist of the GIP, GLP-1 and glucagon receptors and investigated its effects in adults with obesity over 48 weeks.
Explore Each Compound In More Detail
Frequently Asked Questions
What does GLP-1 mean?
GLP-1 stands for glucagon-like peptide-1, a hormone involved in metabolic signalling. Researchers study GLP-1 receptor activity across a range of metabolic and physiological questions.
What is a receptor agonist?
An agonist is a molecule that binds to a receptor and activates signalling through that receptor.
What makes tirzepatide different from semaglutide?
Their receptor targets differ. Semaglutide is studied as a GLP-1 receptor agonist, while tirzepatide acts at both GIP and GLP-1 receptors.
Why is retatrutide described as a triple-receptor agonist?
Published research describes retatrutide as an agonist of the GIP, GLP-1 and glucagon receptors.